1
|
Yan A, Zhang R, Feng C, Feng J. Coronavirus disease 2019-related myocarditis genes contribute to ECMO prognosis. BMC Cardiovasc Disord 2024; 24:375. [PMID: 39026189 PMCID: PMC11264513 DOI: 10.1186/s12872-024-04032-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 07/05/2024] [Indexed: 07/20/2024] Open
Abstract
BACKGROUND Acute myocardial injury, cytokine storms, hypoxemia and pathogen-mediated damage were the major causes responsible for mortality induced by coronavirus disease 2019 (COVID-19)-related myocarditis. These need ECMO treatment. We investigated differentially expressed genes (DEGs) in patients with COVID-19-related myocarditis and ECMO prognosis. METHODS GSE150392 and GSE93101 were analyzed to identify DEGs. A Venn diagram was used to obtain the same transcripts between myocarditis-related and ECMO-related DEGs. Enrichment pathway analysis was performed and hub genes were identified. Pivotal miRNAs, transcription factors, and chemicals with the screened gene interactions were identified. The GSE167028 dataset and single-cell sequencing data were used to validate the screened genes. RESULTS Using a Venn diagram, 229 overlapping DEGs were identified between myocarditis-related and ECMO-related DEGs, which were mainly involved in T cell activation, contractile actin filament bundle, actomyosin, cyclic nucleotide phosphodiesterase activity, and cytokine-cytokine receptor interaction. 15 hub genes and 15 neighboring DEGs were screened, which were mainly involved in the positive regulation of T cell activation, integrin complex, integrin binding, the PI3K-Akt signaling pathway, and the TNF signaling pathway. Data in GSE167028 and single-cell sequencing data were used to validate the screened genes, and this demonstrated that the screened genes CCL2, APOE, ITGB8, LAMC2, COL6A3 and TNC were mainly expressed in fibroblast cells; IL6, ITGA1, PTK2, ITGB5, IL15, LAMA4, CAV1, SNCA, BDNF, ACTA2, CD70, MYL9, DPP4, ENO2 and VEGFC were expressed in cardiomyocytes; IL6, PTK2, ITGB5, IL15, APOE, JUN, SNCA, CD83, DPP4 and ENO2 were expressed in macrophages; and IL6, ITGA1, PTK2, ITGB5, IL15, VCAM1, LAMA4, CAV1, ACTA2, MYL9, CD83, DPP4, ENO2, VEGFC and IL32 were expressed in vascular endothelial cells. CONCLUSION The screened hub genes, IL6, ITGA1, PTK2, ITGB3, ITGB5, CCL2, IL15, VCAM1, GZMB, APOE, ITGB8, LAMA4, LAMC2, COL6A3 and TNFRSF9, were validated using GEO dataset and single-cell sequencing data, which may be therapeutic targets patients with myocarditis to prevent MI progression and adverse cardiovascular events.
Collapse
Affiliation(s)
- An Yan
- Tianjin Chest Hospital, Taierzhuang North Road 261, Jinnan District, Tianjin, China
- Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Taierzhuang North Road 261, Jinnan District, Tianjin, China
| | - Ruiying Zhang
- Tianjin Chest Hospital, Taierzhuang North Road 261, Jinnan District, Tianjin, China
- Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Taierzhuang North Road 261, Jinnan District, Tianjin, China
| | - Chao Feng
- Tianjin Chest Hospital, Taierzhuang North Road 261, Jinnan District, Tianjin, China
- Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Taierzhuang North Road 261, Jinnan District, Tianjin, China
| | - Jinping Feng
- Tianjin Chest Hospital, Taierzhuang North Road 261, Jinnan District, Tianjin, China.
- Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Taierzhuang North Road 261, Jinnan District, Tianjin, China.
| |
Collapse
|
2
|
Biter Hİ, Kalyoncuoğlu M, Tosu AR, Çakal S, Apaydın Z, Gümüşdağ A, Çınar T, Eyüpkoca F, Belen E, Can MM. Prognostic value of the TyG index for in-hospital mortality in nondiabetic COVID-19 patients with myocardial injury. Rev Assoc Med Bras (1992) 2022; 68:1297-1302. [PMID: 36228261 PMCID: PMC9575008 DOI: 10.1590/1806-9282.20220410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 07/02/2022] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE The purpose of this study was to explore the efficacy of the triglyceride glucose (TyG) index on in-hospital mortality in nondiabetic coronavirus disease 2019 (COVID-19) patients with myocardial injury. METHODS This was a retrospective study, which included 218 nondiabetic COVID-19 patients who had myocardial injury. The TyG index was derived using the following equation: log [serum triglycerides (mg/dL) ×fasting blood glucose (mg/dL)/2]. RESULTS Overall, 49 (22.4%) patients died during hospitalization. Patients who did not survive had a higher TyG index than survivors. In multivariate Cox regression analysis, it was found that the TyG index was independently associated with in-hospital death. A TyG index cutoff value greater than 4.97 was predicted in-hospital death in nondiabetic COVID-19 patients with myocardial damage, with 82% sensitivity and 66% specificity. A pairwise evaluation of receiver operating characteristic (ROC) curves demonstrated that the TyG index (AUC: 0.786) had higher discriminatory performance than both triglyceride (AUC: 0.738) and fasting blood glucose (AUC: 0.660) in predicting in-hospital mortality among these patients. CONCLUSIONS The TyG index might be used to identify high-risk nondiabetic COVID-19 patients with myocardial damage.
Collapse
Affiliation(s)
- Halil İbrahim Biter
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Muhsin Kalyoncuoğlu
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Aydın Rodi Tosu
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Sinem Çakal
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Ziya Apaydın
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Ayça Gümüşdağ
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Tufan Çınar
- Health Sciences University, Sultan Abdülhamid Han Training and Research Hospital, Department of Cardiology – Istanbul, Turkey.,Corresponding author:
| | | | - Erdal Belen
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| | - Mehmet Mustafa Can
- Health Sciences University, Sultangazi Haseki Training and Research Hospital, Department of Cardiology – Istanbul, Turkey
| |
Collapse
|
3
|
Sodagar A, Javed R, Tahir H, Razak SIA, Shakir M, Naeem M, Yusof AHA, Sagadevan S, Hazafa A, Uddin J, Khan A, Al-Harrasi A. Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches. Biomolecules 2022; 12:971. [PMID: 35883527 PMCID: PMC9313047 DOI: 10.3390/biom12070971] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 07/03/2022] [Accepted: 07/04/2022] [Indexed: 11/16/2022] Open
Abstract
The number of deaths has been increased due to COVID-19 infections and uncertain neurological complications associated with the central nervous system. Post-infections and neurological manifestations in neuronal tissues caused by COVID-19 are still unknown and there is a need to explore how brainstorming promoted congenital impairment, dementia, and Alzheimer's disease. SARS-CoV-2 neuro-invasion studies in vivo are still rare, despite the fact that other beta-coronaviruses have shown similar properties. Neural (olfactory or vagal) and hematogenous (crossing the blood-brain barrier) pathways have been hypothesized in light of new evidence showing the existence of SARS-CoV-2 host cell entry receptors into the specific components of human nerve and vascular tissue. Spike proteins are the primary key and structural component of the COVID-19 that promotes the infection into brain cells. Neurological manifestations and serious neurodegeneration occur through the binding of spike proteins to ACE2 receptor. The emerging evidence reported that, due to the high rate in the immediate wake of viral infection, the olfactory bulb, thalamus, and brain stem are intensely infected through a trans-synaptic transfer of the virus. It also instructs the release of chemokines, cytokines, and inflammatory signals immensely to the blood-brain barrier and infects the astrocytes, which causes neuroinflammation and neuron death; and this induction of excessive inflammation and immune response developed in more neurodegeneration complications. The present review revealed the pathophysiological effects, molecular, and cellular mechanisms of possible entry routes into the brain, pathogenicity of autoantibodies and emerging immunotherapies against COVID-19.
Collapse
Affiliation(s)
- Aisha Sodagar
- Department of Botany, Faculty of Sciences, University of Agriculture, Faisalabad 38040, Pakistan;
| | - Rasab Javed
- Institute of Microbiology, University of Agriculture, Faisalabad 38040, Pakistan;
| | - Hira Tahir
- Department of Botany, Government College Women University Faisalabad, Faisalabad 38000, Pakistan;
| | - Saiful Izwan Abd Razak
- Bioinspired Device and Tissue Engineering Research Group, School of Biomedical Engineering and Health Sciences, Faculty of Engineering, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor, Malaysia;
- Sports Innovation & Technology Centre, Institute of Human Centred Engineering, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor, Malaysia
| | - Muhammad Shakir
- School of Life Sciences, Northeast Normal University, Changchun 130024, China;
| | - Muhammad Naeem
- College of Life Science, Hebei Normal University, Shijiazhuang 050024, China;
| | - Abdul Halim Abdul Yusof
- School of Chemical and Energy Engineering, Faculty of Engineering, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor, Malaysia;
| | - Suresh Sagadevan
- Nanotechnology & Catalysis Research Centre, University of Malaya, Kuala Lumpur 50603, Kuala Lumpur, Malaysia;
| | - Abu Hazafa
- Department of Biochemistry, Faculty of Sciences, University of Agriculture, Faisalabad 38040, Pakistan
| | - Jalal Uddin
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia;
| | - Ajmal Khan
- Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, Nizwa 616, Oman
| | - Ahmed Al-Harrasi
- Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, Nizwa 616, Oman
| |
Collapse
|
4
|
Rathore SS, Rojas GA, Sondhi M, Pothuru S, Pydi R, Kancherla N, Singh R, Ahmed NK, Shah J, Tousif S, Baloch UT, Wen Q. Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series. Int J Clin Pract 2021; 75:e14470. [PMID: 34235815 DOI: 10.1111/ijcp.14470] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 05/11/2021] [Accepted: 05/24/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Covid-19 is an extremely contagious illness caused by the severe acute respiratory syndrome (SARS-CoV-2) virus. The cardiac involvement in such a public health emergency disease has not been well studied and a conflicting evidence exists on this issue. OBJECTIVE This systematic review article aimed to compile and illustrate clinical characteristics, diagnostic findings, management, and outcomes manifesting in myocarditis linked with Covid-19. METHODS A literature search was accomplished for published eligible articles with MEDLINE/PubMed and Embase databases. All eligible case reports and case series were included from around the world without any language restrictions. For this review, inclusion criteria were laboratory-confirmed SARS-CoV-2 infection cases reporting a diagnosis of acute myocarditis. RESULTS Data from 41 studies describing myocarditis in 42 Covid-19 patients was obtained. The median age of these patients was 43.4 years, with 71.4% of them being men. Fever was the most prevalent presenting symptoms seen in 57% of patients. Hypertension was the most pervasive comorbidity accompanying these patients. Cardiac biomarkers troponin and brain natriuretic peptide (BNP) were raised in almost 90% and 87% of patients, respectively. Electrocardiogram findings were nonspecific and included ST-segment and T-wave changes. Echocardiogram commonly showed left ventricular systolic dysfunction with increased heart size. Cardiac magnetic resonance imaging (CMRI) exhibited myocardial edema and injury. The most prevalent histopathological feature appreciated was diffuse lymphocytic inflammatory infiltrates. Antivirals and corticosteroids were the most frequently used medications. About 38% of patients also needed vasopressor assistance. Out of 42 patients, 67% recovered, and eight died. CONCLUSION Because of the risk of a sudden worsening of patients conditions and myocarditis association with considerable mortality and morbidity, a knowledge of this cardiac complication of Covid-19 disease is crucial for healthcare professionals.
Collapse
Affiliation(s)
| | - Gianpier Alonzo Rojas
- Internal Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru
- Scientific society of medical students, Lima, Perú
| | - Manush Sondhi
- Internal Medicine, Kasturba Medical College, Manipal, India
| | | | - Reshma Pydi
- Internal Medicine, Andhra Medical College, Visakhapatnam, India
| | | | - Romil Singh
- Department of Critical Care, Mayo Clinic, Rochester, MN, USA
| | | | - Jill Shah
- Internal Medicine, Tambov State University named after G.R. Derzhavin, Tambov, Russia
| | - Sohaib Tousif
- Internal Medicine, Ziauddin Medical University, Karachi, Pakistan
| | | | - Qingqing Wen
- Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA
| |
Collapse
|
5
|
Han J, Jia R, Yang C, Jin Z. Impact of the COVID-19 Pandemic on the Management of Acute Myocardial Infarction. Int J Gen Med 2021; 14:3119-3124. [PMID: 34239320 PMCID: PMC8260045 DOI: 10.2147/ijgm.s313165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Accepted: 06/16/2021] [Indexed: 11/23/2022] Open
Abstract
Aim The coronavirus (COVID-19) outbreak in 2019 has negatively impacted the care of patients with other life-threatening diseases, including acute myocardial infarction (AMI). However, there is little published information concerning the depth of the impact on the clinical management and outcome following AMI. Methods We enrolled patients with AMI who received urgent primary percutaneous coronary intervention at the Beijing Tiantan Hospital (Beijing, China) between December 1, 2019 and April 10, 2020. Patients were divided into 2 cohorts, the pre-COVID-19 group (from December 1, 2019 to January 31, 2020) and during-COVID-19 group (from February 1, 2020 to April 10, 2020) for analysis. The door-to-balloon (D to B) time, total hospitalization stay (days) and coronary care unit (CCU) hospitalization days were calculated. New York Heart Association heart functional class (NYHA class), re-hospitalization and death ratio in patients were assessed between the two cohorts. Results A total of 148 AMI patients were enrolled in this study comprising 53 patients pre-COVID-19 group and 95 patients during-COVID-19 group. Patients with AMI during-COVID-19 group had longer symptom onset to hospital time (4.5 [2.0–9.3] vs 3.0 [2.0–5.0] hours, p = 0.013) and D to B time (96 [74–119] vs 67 [52–81] minutes, p <0.001); the D to B time shortened during the study period. The two cohorts did not have significantly different number of hospitalization days, re-hospitalization rates, peak cTnI, BNP or death rates. For the one-year follow-up, the patients in the during-COVID-19 group were classified as NYHA class III–IV more frequently (9 [9.7%] vs 0 [0%], p=0.004). Conclusion The COVID-19 pandemic significantly affected one measure of critical care of patients with AMI, NYHA classification, which may have resulted in increased medical expenses.
Collapse
Affiliation(s)
- Jing Han
- Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Ruofei Jia
- Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Chengzhi Yang
- Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Zening Jin
- Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
| |
Collapse
|
6
|
Larcher R, Besnard N, Akouz A, Rabier E, Teule L, Vandercamere T, Zozor S, Amalric M, Benomar R, Brunot V, Corne P, Barbot O, Dupuy AM, Cristol JP, Klouche K. Admission High-Sensitive Cardiac Troponin T Level Increase Is Independently Associated with Higher Mortality in Critically Ill Patients with COVID-19: A Multicenter Study. J Clin Med 2021; 10:1656. [PMID: 33924475 PMCID: PMC8070238 DOI: 10.3390/jcm10081656] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 04/08/2021] [Accepted: 04/10/2021] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND In coronavirus disease 2019 (COVID-19) patients, increases in high-sensitive cardiac troponin T (hs-cTnT) have been reported to be associated with worse outcomes. In the critically ill, the prognostic value of hs-cTnT, however, remains to be assessed given that most previous studies have involved a case mix of non- and severely ill COVID-19 patients. METHODS We conducted, from March to May 2020, in three French intensive care units (ICUs), a multicenter retrospective cohort study to assess in-hospital mortality predictability of hs-cTnT levels in COVID-19 patients. RESULTS 111 laboratory-confirmed COVID-19 patients (68% of male, median age 67 (58-75) years old) were included. At ICU admission, the median Charlson Index, Simplified Acute Physiology Score II, and PaO2/FiO2 were at 3 (2-5), 37 (27-48), and 140 (98-154), respectively, and the median hs-cTnT serum levels were at 16.0 (10.1-31.9) ng/L. Seventy-five patients (68%) were mechanically ventilated, 41 (37%) were treated with norepinephrine, and 17 (15%) underwent renal replacement therapy. In-hospital mortality was 29% (32/111) and was independently associated with lower PaO2/FiO2 and higher hs-cTnT serum levels. CONCLUSIONS At ICU admission, besides PaO2/FiO2, hs-cTnT levels may allow early risk stratification and triage in critically ill COVID-19 patients.
Collapse
Affiliation(s)
- Romaric Larcher
- Biochemistry and Hormonology Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (S.Z.); (A.-M.D.); (J.-P.C.)
- PhyMedExp, University of Montpellier, INSERM, CNRS, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, 34090 Montpellier, France;
| | - Noemie Besnard
- Intensive Care Medicine Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (N.B.); (M.A.); (R.B.); (V.B.); (P.C.)
| | - Aziz Akouz
- Intensive Care Unit, Hospital of Perpignan, 66000 Perpignan, France; (A.A.); (L.T.); (O.B.)
| | - Emmanuelle Rabier
- Intensive Care Unit, Hospital of Narbonne, 11100 Narbonne, France; (E.R.); (T.V.)
| | - Lauranne Teule
- Intensive Care Unit, Hospital of Perpignan, 66000 Perpignan, France; (A.A.); (L.T.); (O.B.)
| | - Thomas Vandercamere
- Intensive Care Unit, Hospital of Narbonne, 11100 Narbonne, France; (E.R.); (T.V.)
| | - Samuel Zozor
- Biochemistry and Hormonology Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (S.Z.); (A.-M.D.); (J.-P.C.)
| | - Matthieu Amalric
- Intensive Care Medicine Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (N.B.); (M.A.); (R.B.); (V.B.); (P.C.)
| | - Racim Benomar
- Intensive Care Medicine Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (N.B.); (M.A.); (R.B.); (V.B.); (P.C.)
| | - Vincent Brunot
- Intensive Care Medicine Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (N.B.); (M.A.); (R.B.); (V.B.); (P.C.)
| | - Philippe Corne
- Intensive Care Medicine Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (N.B.); (M.A.); (R.B.); (V.B.); (P.C.)
| | - Olivier Barbot
- Intensive Care Unit, Hospital of Perpignan, 66000 Perpignan, France; (A.A.); (L.T.); (O.B.)
| | - Anne-Marie Dupuy
- Biochemistry and Hormonology Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (S.Z.); (A.-M.D.); (J.-P.C.)
| | - Jean-Paul Cristol
- Biochemistry and Hormonology Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (S.Z.); (A.-M.D.); (J.-P.C.)
- PhyMedExp, University of Montpellier, INSERM, CNRS, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, 34090 Montpellier, France;
| | - Kada Klouche
- PhyMedExp, University of Montpellier, INSERM, CNRS, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, 34090 Montpellier, France;
- Intensive Care Medicine Department, Lapeyronie Hospital, University Hospital of Montpellier, 34090 Montpellier, France; (N.B.); (M.A.); (R.B.); (V.B.); (P.C.)
| |
Collapse
|
7
|
Nolan JP, Ornato JP, Parr MJA, Perkins GD, Soar J. Resuscitation highlights in 2020. Resuscitation 2021; 162:1-10. [PMID: 33577963 DOI: 10.1016/j.resuscitation.2021.01.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 01/31/2021] [Indexed: 10/22/2022]
Abstract
BACKGROUND This review is the latest in a series of regular annual reviews undertaken by the editors and aims to highlight some of the key papers published in Resuscitation during 2020. The number of papers submitted to the Journal in 2020 increased by 25% on the previous year.MethodsHand-searching by the editors of all papers published in Resuscitation during 2020. Papers were selected based on then general interest and novelty and were categorised into general themes.ResultsA total of 103 papers were selected for brief mention in this review.ConclusionsResuscitation science continues to evolve rapidly and incorporate all links in the chain of survival.
Collapse
Affiliation(s)
- J P Nolan
- University of Warwick, Warwick Medical School, Coventry, CV4 7AL, UK; Anaesthesia and Intensive Care Medicine, Royal United Hospital, Bath, BA1 3NG, UK.
| | - J P Ornato
- Department of Emergency Medicine, Virginia Commonwealth University Health, Richmond, VA, USA.
| | - M J A Parr
- Intensive Care, Liverpool and Macquarie University Hospitals, University of New South Wales and Macquarie University, Sydney, Australia.
| | - G D Perkins
- Critical Care Medicine, University of Warwick, Warwick Medical School and University Hospitals Birmingham NHS Foundation Trust, Coventry, CV4 7AL, UK.
| | - J Soar
- Anaesthesia and Intensive Care Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol, BS10 5NB, UK.
| |
Collapse
|